Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Maker of Ingredient for Fen-Phen Not Liable
The maker of a component ingredient of the diet drug Fen-Phen cannot be sued over the drug, a Philadelphia Common Pleas Court judge has ruled, because the trial court found that the defendant in the mass tort litigation that resulted in a $4 billion settlement was solely responsible. Sokoloski v. American Home Products Corp., PICS NO. 03-0073. In addition, as the producer of only a component ingredient of Fen-Phen, Les Servier owed no duty to the plaintiffs.
The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.
The parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.
This article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.
There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.
This article explores legal developments over the past year that may impact compliance officer personal liability.